BioSpace News Archive

Vivos Therapeutics, Inc. (“Vivos” or the “Company’’) (NASDAQ: VVOS), today reported financial results and operating highlights for the fourth quarter and full year ended December 31, 2021.

Armata Pharmaceuticals, Inc. announced that, following a vote in favor of the transaction by the Armata shareholders, the Company has completed the closing of the second and final tranche of the Company’s $45 million private placement of its common stock with Innoviva Strategic Opportunities LLC, a wholly-owned subsidiary of Innoviva, Inc.

Personalis, Inc., a leader in advanced genomics for cancer, announced that its management team will present at the 21st Annual Needham Virtual Healthcare Conference on Wednesday, April 13, 2022 at 2:15 p.m. Eastern Time.

Idera Pharmaceuticals, Inc. reported its financial and operational results for the fourth quarter and year ended December 31, 2021.

USWM, LLC, and Adamis Pharmaceuticals Corporation, announced the U.S. launch and availability of ZIMHI™ 5 mg/0.5 mL. ZIMHI is a high-dose naloxone injection product FDA-approved for use in the treatment of opioid overdose as emergency therapy in settings where opioids may be present.

Pulse Biosciences, Inc., a novel bioelectric medicine company commercializing the CellFX® System powered by Nano-Pulse Stimulation™ technology, announced financial results for the fourth quarter and full year of 2021.

ValenzaBio, Inc. today announced that its investigational new drug (IND) application for its lead drug candidate, VB421, for the treatment of thyroid eye disease (TED), has been cleared by the U.S. Food and Drug Administration (FDA) for clinical evaluation.

Venus Concept Inc. today announced it has submitted a 510(k) premarket notification (“510(k)”) to the U.S. Food and Drug Administration (“FDA”), which is intended to obtain a general clinical indication related to the use of its Aime™ next generation robotic technology for tissue excision and skin resurfacing.

ABVC BioPharma, Inc. today announced its financial and operating results for the fiscal year ended December 31, 2021.

Precision Optics Corporation, Inc. announced today that it will be participating in the Lytham Partners Spring 2022 Investor Conference taking place virtually on April 4-7, 2022.